|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2002-3-15
|
|
pubmed:abstractText |
The clinical benefit of adoptive transfer of MHC-restricted cytotoxic T lymphocytes(CTL) for the treatment of cancer is hampered by the low success rate to generate antitumor CTLs. To bypass the need for tumor-specific CTL, we developed a strategy that allows for grafting of human T lymphocytes with MHC-restricted antigen specificity using in vitro selected human Fab fragments fused to the Fc(epsilon)RI-gamma signaling molecule. Retroviral introduction of a Fab-based chimeric receptor specific for MAGE-A1/HLA-A1 into primary human T lymphocytes resulted in binding of relevant peptide/MHC complexes. Transduced T lymphocytes responded to native MAGE-A1/HLA-A1POS target cells by specific cytokine production and cytolysis. Therefore, peptide/MHC-specific Fab fragments represent new alternatives to TCR to confer human T lymphocytes with tumor specificity, which provides a promising rationale for developing immunogene therapies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0969-7128
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1601-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11894998-Antigens, Neoplasm,
pubmed-meshheading:11894998-Epitopes,
pubmed-meshheading:11894998-Gene Therapy,
pubmed-meshheading:11894998-Genetic Vectors,
pubmed-meshheading:11894998-HLA-A1 Antigen,
pubmed-meshheading:11894998-Humans,
pubmed-meshheading:11894998-Immunoglobulin Fab Fragments,
pubmed-meshheading:11894998-Immunotherapy, Adoptive,
pubmed-meshheading:11894998-Melanoma,
pubmed-meshheading:11894998-Melanoma-Specific Antigens,
pubmed-meshheading:11894998-Neoplasm Proteins,
pubmed-meshheading:11894998-Peptide Library,
pubmed-meshheading:11894998-Receptors, Immunologic,
pubmed-meshheading:11894998-Retroviridae,
pubmed-meshheading:11894998-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:11894998-Transduction, Genetic,
pubmed-meshheading:11894998-Tumor Cells, Cultured
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.
|
|
pubmed:affiliation |
Department of Clinical and Tumor Immunology, Academic Hospital Rotterdam/Daniel den Hoed Cancer Center, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
